載入中
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
前收盤價
US$6.72
+US$0.29 · +4.51%
盤中時間採用ET。市場資料可能有所延遲。
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
日內區間
目前US$6.72
52週區間
目前US$6.72
盤中時間採用ET。市場資料可能有所延遲。
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
日內區間
目前US$6.72
52週區間
目前US$6.72
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3426.4萬 USD | 6869.6萬 USD | 4872.7萬 USD | 2509.8萬 USD | 1.16億 USD |
| 毛利 | 3426.4萬 USD | 6869.6萬 USD | 4872.7萬 USD | 2509.8萬 USD | 1.16億 USD |
| 研究與開發 | 5417.2萬 USD | 5955.9萬 USD | 5337.5萬 USD | 4612.2萬 USD | 1.15億 USD |
| 銷售、一般及管理費用 | 3224萬 USD | 3529.9萬 USD | 3908.8萬 USD | 4128.4萬 USD | 3966.7萬 USD |
| 營業費用 | 8641.2萬 USD | 9485.8萬 USD | 9246.3萬 USD | 8740.6萬 USD | 1.55億 USD |
| 利息收入 | 423.9萬 USD | 676.3萬 USD | 768.6萬 USD | 347.3萬 USD | 20.8萬 USD |
| 利息支出 | 142.2萬 USD | 178.2萬 USD | 223萬 USD | 111.1萬 USD | 13.2萬 USD |
| 折舊和攤銷 | 275.3萬 USD | 457.7萬 USD | 825.5萬 USD | 900.4萬 USD | 1019.7萬 USD |
| 營業利益 | −5214.8萬 USD | −2616.2萬 USD | −4373.6萬 USD | −6230.8萬 USD | −3937.6萬 USD |
| 淨利 | −4572.4萬 USD | 716.7萬 USD | −6131.9萬 USD | −1.12億 USD | −3060.2萬 USD |
公司資料更新於 2026年10月12日。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI594.5萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM394.69萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF228.48萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO105.23萬0.01%180億 USD0.06%US$112.66+0.50%
Fidelity Enhanced Small Cap ETFFESM80.04萬0.01%64.1億 USD0.28%US$45.46+0.46%
iShares Micro-Cap ETFIWC48.3萬0.04%13.17億 USD0.60%US$183+0.11%
Avantis U.S. Small Cap Equity ETFAVSC23.59萬0.01%30.82億 USD0.25%US$69.98+0.03%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC23.49萬0.02%10.45億 USD0.20%US$86.29+0.43%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCAvantis U.S. Small Cap Equity ETFAVSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
